CN107980040B - 作为组蛋白去乙酰酶6抑制剂的1,3,4-噁二唑磺酰胺衍生物及含其的医药组合物 - Google Patents
作为组蛋白去乙酰酶6抑制剂的1,3,4-噁二唑磺酰胺衍生物及含其的医药组合物 Download PDFInfo
- Publication number
- CN107980040B CN107980040B CN201680025249.5A CN201680025249A CN107980040B CN 107980040 B CN107980040 B CN 107980040B CN 201680025249 A CN201680025249 A CN 201680025249A CN 107980040 B CN107980040 B CN 107980040B
- Authority
- CN
- China
- Prior art keywords
- methyl
- sulfonamide
- alkyl
- stirred
- reaction mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150106177 | 2015-07-27 | ||
| KR10-2015-0106177 | 2015-07-27 | ||
| PCT/KR2016/008218 WO2017018805A1 (en) | 2015-07-27 | 2016-07-27 | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107980040A CN107980040A (zh) | 2018-05-01 |
| CN107980040B true CN107980040B (zh) | 2021-11-26 |
Family
ID=57885712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680025249.5A Active CN107980040B (zh) | 2015-07-27 | 2016-07-27 | 作为组蛋白去乙酰酶6抑制剂的1,3,4-噁二唑磺酰胺衍生物及含其的医药组合物 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10464911B2 (enExample) |
| EP (1) | EP3328844B1 (enExample) |
| JP (1) | JP6538266B2 (enExample) |
| KR (1) | KR101799005B1 (enExample) |
| CN (1) | CN107980040B (enExample) |
| AU (1) | AU2016299486B2 (enExample) |
| BR (1) | BR112017027798B1 (enExample) |
| CA (1) | CA2987570C (enExample) |
| DK (1) | DK3328844T3 (enExample) |
| ES (1) | ES2774510T3 (enExample) |
| HR (1) | HRP20200280T1 (enExample) |
| HU (1) | HUE048534T2 (enExample) |
| MX (1) | MX376585B (enExample) |
| MY (1) | MY194018A (enExample) |
| NZ (1) | NZ736432A (enExample) |
| PH (1) | PH12017501939A1 (enExample) |
| PL (1) | PL3328844T3 (enExample) |
| PT (1) | PT3328844T (enExample) |
| RU (1) | RU2695227C9 (enExample) |
| TW (1) | TWI694074B (enExample) |
| WO (1) | WO2017018805A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016258188B2 (en) | 2015-05-07 | 2021-08-26 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
| KR20180002730A (ko) | 2015-05-07 | 2018-01-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법 |
| NZ739026A (en) | 2015-07-27 | 2019-03-29 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| KR101799005B1 (ko) | 2015-07-27 | 2017-11-17 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
| BR112018002304B1 (pt) | 2015-08-04 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
| WO2017065473A1 (en) | 2015-10-12 | 2017-04-20 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
| TW201910328A (zh) * | 2017-07-31 | 2019-03-16 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
| KR102059027B1 (ko) * | 2018-01-12 | 2019-12-24 | 주식회사 비엔에이치리서치 | Hdac6 억제제를 유효성분으로 포함하는 가려움증 예방 또는 치료용 약제학적 조성물 |
| KR102316234B1 (ko) * | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| US12084436B2 (en) | 2019-01-30 | 2024-09-10 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| BR112021020682A2 (pt) | 2019-04-17 | 2021-12-07 | Fund Kertor | Derivados de 1,3,4-oxadiazol como inibidores de histona deacetilase |
| MX2021014315A (es) | 2019-05-31 | 2022-01-04 | Chong Kun Dang Pharmaceutical Corp | Compuestos derivados de 1,3,4-oxadiazol homoftalimida como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. |
| CA3144985A1 (en) | 2019-06-27 | 2020-12-30 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Hdac6-activated macrophages, compositions, and uses thereof |
| AR120040A1 (es) | 2019-09-27 | 2022-01-26 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
| CA3165424A1 (en) | 2019-12-20 | 2021-06-24 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| KR102537616B1 (ko) * | 2020-02-25 | 2023-05-26 | 주식회사 종근당 | 히스톤 탈아세틸화 효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| MX2023000625A (es) * | 2020-07-14 | 2023-02-22 | Chong Kun Dang Pharmaceutical Corp | Nuevos compuestos como inhibidor de histona desacetilasa 6, y composicion farmaceutica que los comprende. |
| JP2023537052A (ja) | 2020-08-07 | 2023-08-30 | イタルファルマコ ソシエタ ペル アチオニ | 新規オキサジアゾール系の選択的ｈｄａｃ６阻害剤 |
| CA3211625A1 (en) * | 2021-04-08 | 2022-10-13 | Chang Sik Lee | 1,3,4-oxadiazole thiocarbonyl compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same |
| EP4326263A1 (en) | 2021-04-23 | 2024-02-28 | Tenaya Therapeutics, Inc. | Hdac6 inhibitors for use in the treatment of dilated cardiomyopathy |
| TW202308619A (zh) | 2021-05-04 | 2023-03-01 | 美商特納亞治療股份有限公司 | 用於治療代謝疾病和hfpef的hdac6抑制劑 |
| TW202412772A (zh) | 2022-07-19 | 2024-04-01 | 義大利商義大利藥品股份有限公司 | 作為選擇性組蛋白去乙醯酶６抑制劑之１，３，４－㗁二唑衍生物 |
| EP4568949A1 (en) | 2022-08-08 | 2025-06-18 | Italfarmaco SpA | Difluoro- and trifluoro-acetyl hydrazides as selective hdac6 inhibitors |
| KR20240035172A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
| IL319658A (en) * | 2022-10-14 | 2025-05-01 | Chong Kun Dang Pharmaceutical Corp | Sulfoximine compounds as histone deacetylase 6 inhibitors, and a pharmaceutical composition comprising the same |
| WO2025215092A1 (en) | 2024-04-10 | 2025-10-16 | Institut National de la Santé et de la Recherche Médicale | Selective hdac6 inhibitors for use in the treatment of myotonic dystrophy type 1 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0276432A3 (de) | 1986-12-12 | 1988-10-26 | Ciba-Geigy Ag | Schädlingsbekämpfungsmittel |
| KR100265385B1 (ko) | 1998-02-27 | 2000-11-01 | 윤여표 | 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물 |
| US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| CA2462601A1 (en) | 2001-10-03 | 2003-04-10 | Pharmacia Corporation | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade |
| IL162498A0 (en) | 2001-12-20 | 2005-11-20 | Bristol Myers Squibb Co | (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same |
| AU2006270322A1 (en) | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP2388263A1 (en) | 2005-08-04 | 2011-11-23 | Sirtris Pharmaceuticals, Inc. | Imidazo[2,1-b]thiazole derivatives as sirtuin modulators |
| WO2007032445A1 (ja) | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
| NZ571271A (en) | 2006-03-23 | 2011-10-28 | Biota Europe Ltd | The use of benzamide or pyridinamide derivatives as antibacterial agents |
| WO2007143822A1 (en) | 2006-06-14 | 2007-12-21 | Methylgene Inc. | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
| EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| RU2482877C2 (ru) | 2006-12-11 | 2013-05-27 | Дженентек, Инк. | Композиции и способы для лечения опухоли |
| WO2009010479A2 (en) | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
| KR100903743B1 (ko) | 2007-08-28 | 2009-06-19 | 전병태 | 소화기계 질환개선 및 예방용 식품 조성물 |
| JP2011502133A (ja) | 2007-11-02 | 2011-01-20 | メシルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
| SG185925A1 (en) | 2007-11-02 | 2012-12-28 | Momenta Pharmaceuticals Inc | Non-anticoagulant polysaccharide compositions |
| CA2731730C (en) * | 2008-07-23 | 2017-06-13 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
| CN102802623A (zh) | 2009-04-20 | 2012-11-28 | 人类健康研究所 | 含有1，3，4-恶二唑衍生物的化合物、组合物和方法 |
| WO2010126002A1 (ja) | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
| JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
| WO2011011186A2 (en) | 2009-07-22 | 2011-01-27 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
| KR101781663B1 (ko) | 2010-01-13 | 2017-09-25 | 템페로 파마슈티칼즈, 인크. | 히스톤 데아세틸라제 효소를 억제하기 위한 화합물 및 이를 제조하는 방법 |
| JP2013517281A (ja) | 2010-01-13 | 2013-05-16 | テンペロ、ファーマシューティカルズ、インコーポレイテッド | 化合物及び方法 |
| LT2526093T (lt) | 2010-01-22 | 2016-10-10 | Acetylon Pharmaceuticals, Inc. | Grįžtamieji amido junginiai kaip baltymo deacetilazės inhibitoriai ir jų panaudojimo būdai |
| EP2539327A1 (en) | 2010-02-25 | 2013-01-02 | Piramal Enterprises Limited | Oxadiazole compounds, their preparation and use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| CA2798763A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| RU2601550C2 (ru) | 2010-12-09 | 2016-11-10 | Вокхардт Лимитед | Кетолидные соединения |
| KR101262870B1 (ko) | 2011-01-28 | 2013-05-09 | 환인제약 주식회사 | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 |
| EP2729454B1 (en) | 2011-07-08 | 2015-09-16 | Novartis AG | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
| JP6169076B2 (ja) | 2011-07-20 | 2017-07-26 | ザ ジェネラル ホスピタル コーポレイション | 骨疾患の処置のためのヒストン脱アセチル化酵素６選択的阻害剤 |
| WO2013041407A1 (en) | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| US9499479B2 (en) | 2011-10-03 | 2016-11-22 | The Trustees Of Columbia University In The City Of New York | Molecules that selectively inhibit histone deacetylase 6 relative to histone deacetylase 1 |
| WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
| WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
| BR112014012815A8 (pt) | 2011-11-28 | 2017-06-20 | Novartis Ag | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença |
| US9345905B2 (en) | 2011-11-29 | 2016-05-24 | Nanjing Allgen Pharma Co. Ltd. | Heterocyclic amides compounds which are HDAC6 inhibitors and used as anti-tumoral agents |
| CA2866707A1 (en) | 2012-03-07 | 2013-09-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Selective histone deactylase 6 inhibitors |
| CU24345B1 (es) | 2013-09-06 | 2018-05-08 | Aurigene Discovery Tech Ltd | Derivados de 1,3,4-oxadiazol y 1,3,4-tiadiazol como inmunomoduladores |
| DK3080125T3 (en) * | 2013-12-12 | 2019-01-07 | Chong Kun Dang Pharmaceutical Corp | PRESENT UNKNOWN AZA DERIVATIVE DERIVATIVES AS SELECTIVE HISTONDEACETYLASE (HDAC) INHIBITORS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THESE |
| CN104744446B (zh) | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| ES2713700T3 (es) * | 2014-11-24 | 2019-05-23 | Medifron Dbt Inc | Derivados de carboxamida y urea a base de oxazol y tiazol sustituidos como ligandos del receptor de vainilloide II |
| CN106349451B (zh) | 2015-07-14 | 2020-11-13 | 罗门哈斯公司 | 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法 |
| NZ739026A (en) | 2015-07-27 | 2019-03-29 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| KR101799005B1 (ko) | 2015-07-27 | 2017-11-17 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 설프아마이드 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
| BR112018002304B1 (pt) | 2015-08-04 | 2023-12-19 | Chong Kun Dang Pharmaceutical Corp | Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos |
| WO2017065473A1 (en) | 2015-10-12 | 2017-04-20 | Chong Kun Dang Pharmaceutical Corp. | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
-
2016
- 2016-07-27 KR KR1020160095326A patent/KR101799005B1/ko active Active
- 2016-07-27 RU RU2018106904A patent/RU2695227C9/ru active
- 2016-07-27 CA CA2987570A patent/CA2987570C/en active Active
- 2016-07-27 MX MX2017017090A patent/MX376585B/es active IP Right Grant
- 2016-07-27 DK DK16830838.5T patent/DK3328844T3/da active
- 2016-07-27 BR BR112017027798-0A patent/BR112017027798B1/pt active IP Right Grant
- 2016-07-27 EP EP16830838.5A patent/EP3328844B1/en active Active
- 2016-07-27 HU HUE16830838A patent/HUE048534T2/hu unknown
- 2016-07-27 NZ NZ736432A patent/NZ736432A/en unknown
- 2016-07-27 PT PT168308385T patent/PT3328844T/pt unknown
- 2016-07-27 US US15/747,850 patent/US10464911B2/en active Active
- 2016-07-27 MY MYPI2017703935A patent/MY194018A/en unknown
- 2016-07-27 WO PCT/KR2016/008218 patent/WO2017018805A1/en not_active Ceased
- 2016-07-27 TW TW105123853A patent/TWI694074B/zh active
- 2016-07-27 PL PL16830838T patent/PL3328844T3/pl unknown
- 2016-07-27 CN CN201680025249.5A patent/CN107980040B/zh active Active
- 2016-07-27 JP JP2018504096A patent/JP6538266B2/ja active Active
- 2016-07-27 HR HRP20200280TT patent/HRP20200280T1/hr unknown
- 2016-07-27 AU AU2016299486A patent/AU2016299486B2/en active Active
- 2016-07-27 ES ES16830838T patent/ES2774510T3/es active Active
-
2017
- 2017-10-24 PH PH12017501939A patent/PH12017501939A1/en unknown
Non-Patent Citations (2)
| Title |
|---|
| 2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: Design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors;H. Rajak et al.;《Bioorg. Med. Chem. Lett.》;20110808;第21卷;第5735–5738页 * |
| Synthesis and evaluation of lysine derived sulfamides as histone deacetylase inhibitors;S. Manku et al.;《Bioorg. Med. Chem. Lett.》;20090223;第19卷;第1866–1870页 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107980040B (zh) | 作为组蛋白去乙酰酶6抑制剂的1,3,4-噁二唑磺酰胺衍生物及含其的医药组合物 | |
| TWI639587B (zh) | 作為組蛋白去乙醯酶６抑制劑之１，３，４－二唑磺胺衍生物及含彼之醫藥組合物 | |
| CN108026056B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑酰胺衍生物化合物及其药物组合物 | |
| CN108137518B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生物化合物及包含其的药物组合物 | |
| CN106232584A (zh) | 作为组蛋白脱乙酰酶6抑制剂的新型化合物和包含其的药物组合物 | |
| CN113924296A (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-噁二唑衍生化合物及包含其的药物组合物 | |
| TWI617545B (zh) | 作為選擇性組織蛋白去乙醯酶抑制劑之雜環烷基衍生物化合物及包含其之醫藥組合物 | |
| TWI770841B (zh) | 作為組蛋白脫乙醯基酶６抑制劑之1,3,4-㗁二唑衍生物化合物及包含其的醫藥組合物 | |
| TWI844004B (zh) | 二唑硫羰基化合物及包含該等化合物之醫藥組合物 | |
| TWI786553B (zh) | 二唑衍生物化合物及包含其的醫藥組合物 | |
| TWI807300B (zh) | 二唑衍生物化合物及包含其的藥物組合物 | |
| HK1251549B (zh) | 作为组蛋白去乙醯酶6抑制剂的1，3，4-恶二唑磺醯胺衍生物及含其的医药组合物 | |
| HK40074260B (zh) | 作为组蛋白脱乙醯酶6抑制剂的1，3，4-恶二唑衍生物化合物以及包含其的药物组合物 | |
| HK40060493A (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| HK1251939B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1,3,4-恶二唑酰胺衍生物化合物及其药物组合物 | |
| HK40074260A (en) | 1,3,4 oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| HK40077295B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1，3，4-恶二唑衍生物化合物以及包含其的药物组合物 | |
| WO2024121709A1 (en) | Papain-like protease (plpro) inhibitors | |
| HK40075698B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1，3，4-恶二唑衍生物化合物以及包含其的药物组合物 | |
| HK40086988A (zh) | 作为组蛋白去乙酰酶6抑制剂的新化合物及包含该化合物的药物组合物 | |
| HK1251571B (zh) | 作为组蛋白脱乙酰基酶6抑制剂的1，3，4-恶二唑磺酰胺衍生化合物及含有其的医药组合物 | |
| HK40077295A (en) | 1,3,4 oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| HK1227394A1 (en) | Novel compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | |
| HK1251556B (zh) | 用作选择性组蛋白脱乙酰酶抑制剂的杂环烷基衍生化合物及含其的药物组合物 | |
| HK1254756B (zh) | 作为组蛋白脱乙酰酶6抑制剂的1，3，4-恶二唑衍生物化合物及包含其的药物组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1251549 Country of ref document: HK |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |